What does the evidence say about Probiotics Depression Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Probiotics Depression Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Probiotic monotherapy was associated with a small but statistically significant reduction in depressive symptoms (SMD = -0.38, 95% CI: -0.57 to -0.18, p = 0.0002, I² = 51%). [Haiyan L (2026); evidence level 1] - Conclusion Probiotic monotherapy may provide modest improvement in depressive symptoms and is generally safe for unmedicated individuals with mild to moderate depression. [Haiyan L (2026); evidence level 1] - Objective To assess the independent efficacy and safety of probiotics in unmedicated adults with depression, with a focus on studies approximating monotherapy conditions. [Haiyan L (2026); evidence level 1] - Methods This systematic review and meta-analysis followed PRISMA 2020 guidelines and was registered with PROSPERO (CRD420251015474). [Haiyan L (2026); evidence level 1] - Conclusion In this randomized, double‑blind, placebo‑controlled pilot trial, both probiotic and placebo groups showed significant improvements in depressive and anxiety symptoms over time, with no significant between‑group differences. [Mosavat SH (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.